benzyl cyanate | 75403-69-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl cyanate
• CAS: 75403-69-9
• 化学式: C₈H₇NO
• 分子量: 133.15
• InChiKey: WIJRMGQOERPOJA-UHFFFAOYSA-N

物化性质

• 沸点：
  67-70 °C(Press: 3 Torr)
• 密度：
  1.091±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzyl cyanate 在 1,5-二氮杂双环[4.3.0]壬-5-烯 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 methyl 3-amino-4-(phenylmethyl)furan-2-carboxylate
  参考文献：
  名称：

  7-取代-2-氨基噻吩并呋喃和呋喃并[3,2- d ]嘧啶的新合成

  摘要：

  在最近的出版物中，我们已经描述了7-取代的-2-氨基-1,5-二氢-4 H-吡咯并[3,2 - d ]嘧啶-4-酮的合成，它们是嘌呤酶的有效抑制剂。来自相应的3-氨基吡咯-2-羧酸酯的核苷磷酸化酶。合成中的关键步骤是氨基与高反应性鸟苷酸化试剂3或4缩合，然后进行环合。呋喃[3,2- d ]嘧啶-4-酮和噻吩并[3,2- d] pyridin-4-one是紧密相关的环系统。然而，在文献中尚未报道这些环带有2-氨基取代基，该取代基将由这种鸟苷化反应产生。在本报告中，基于改进的吡咯合成方法描述了新型呋喃5的合成方法（方案1）。描述了新型噻吩6的合成。研究了5和6的鸟嘌呤化并将其与2比较。在温和的酸催化下5和6的3-氨基不能与3或4反应。2的条件容易凝结。通过在汞催化下生成3的碳二亚胺中间体，最终实现鸟苷酸化，得到鸟苷化的加合物，将其转变为新型的2-氨基噻吩并呋喃并[3,2 - d ]嘧啶-4-酮16。

  DOI：

  10.1002/jhet.5570360214
• 作为产物：
  描述：

  苄胺 、 alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 benzyl cyanate
  参考文献：
  名称：

  Organosilicon synthesis of isocyanates: II. Synthesis of aliphatic, carbocyclic, and fatty-aromatic isocyanates

  摘要：

  Silylation of a series of aliphatic, carbocyclic, and fatty-aromatic amines gave the corresponding silyl derivatives whose yield depended on the electronic and steric structure of the substrate and the nature of the silylating agent. The yield of isocyanates obtained by phosgenation of the silyl derivatives under mild conditions decreased in going from aliphatic amines to benzylamines and rose as the length of the alkyl chain in fatty-aromatic amines extended. The most convenient procedure for the synthesis of low-boiling alkyl isocyanates was found to be based on the transformation of amines or ammonium salts into silyl or silyl silyl-carabamates. followed by pyrolysis of the latter in the presence of trichloro(phenyl)silane.

  DOI：

  10.1134/s1070363206030182

文献信息

• COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDFGR
  申请人：BLUEPRINT MEDICINES CORPORATION

  公开号：US20170022206A1

  公开（公告）日：2017-01-26

  Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.

  这里描述了用于治疗与KIT和PDGFR相关疾病的化合物和组合物。
• [EN] F2 DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS DE F2 COMME AGENTS ANTIBACTÉRIENS
  申请人：PENN STATE RES FOUND

  公开号：WO2013154793A1

  公开（公告）日：2013-10-17

  A compound or its pharmaceutically acceptable salt, as well as a pharmaceutical composition containing that compound or salt dissolved or dispersed in a pharmaceutically acceptable carrier, and a method of using that compound or salt in an antibacterial treatment. A contemplated compound corresponds in structure to structural Formula I or a pharmaceutically acceptable salt of that compound, wherein V is O or NR9, Y is halogen, OR10, C1-C4 hydrocarbyl or NHR10, Z is NR2-X-R1 or CH2-R8, n is 1-6, X is H, S(O)2, C(O), C(O)NR7, C(NH)NR7 or C (O) O, and R1, R2, R7 ' R8, R9 and R10 are defined within. ( l )

  一种化合物或其药学上可接受的盐，以及含有该化合物或盐溶解或分散在药学上可接受的载体中的制药组合物，以及使用该化合物或盐进行抗菌治疗的方法。所考虑的化合物在结构上对应于结构式I或该化合物的药学上可接受的盐，其中V为O或NR9，Y为卤素，OR10，C1-C4烃基或NHR10，Z为NR2-X-R1或CH2-R8，n为1-6，X为H，S(O)2，C(O)，C(O)NR7，C(NH)NR7或C(O)O，R1，R2，R7，R8，R9和R10在内部有定义。
• DENTAL POLYMERIZABLE MONOMER COMPOSITIONS
  申请人：MITSUI CHEMICALS, INC.

  公开号：US20170181932A1

  公开（公告）日：2017-06-29

  Provided are dental polymerizable monomer compositions that can give cured products having high toughness and high rigidity, and dental compositions containing such dental polymerizable monomer compositions and cured products thereof having high mechanical properties. The dental polymerizable monomer composition includes a urethane acrylate compound (A) and a polymerizable compound (B) having at least one polymerizable group selected from methacryloyl groups and acryloyl groups, the urethane acrylate compound (A) being obtained by reacting a specific hydroxyacrylate (a1) with a diisocyanate (a2) having two isocyanate groups bonded to a divalent C 6-9 aromatic hydrocarbon group or a divalent C 6-9 bridged cyclic hydrocarbon group via a methylene group optionally substituted with a hydrocarbon group in place of a hydrogen atom, the proportion of the number of acryloyl groups present in the urethane acrylate compound (A) being 10% to less than 90% relative to the total number of (meth)acryloyl groups in the monomer composition.

  提供了一种牙科可聚合单体组合物，可使固化产物具有高韧性和高刚度，并且含有这种牙科可聚合单体组合物和具有高机械性能的固化产物的牙科组合物。该牙科可聚合单体组合物包括一种脲基丙烯酸酯化合物（A）和一种具有至少一种可聚合基团，所述可聚合基团选自甲基丙烯酰基团和丙烯酰基团的可聚合化合物（B），脲基丙烯酸酯化合物（A）是通过将特定的羟基丙烯酸酯（a1）与具有两个异氰酸基团与一个二价C6-9芳香烃基或一个二价C6-9桥环烃基通过一个亚甲基团或者可选地替代氢原子的烃基的甲烷基团相结合的二异氰酸酯（a2）反应而得到的，相对于单体组合物中（甲）丙烯酰基团的总数，脲基丙烯酸酯化合物（A）中存在的丙烯酰基团的比例为10%至90%。
• [EN] ASPARTYL PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ASPARTYLE PROTÉASE
  申请人：MEDIVIR AB

  公开号：WO2009053277A1

  公开（公告）日：2009-04-30

  The invention provides compounds of the formula (I) wherein A is selected from the partial structures A1, A2 and A3; Ry and Ry' are both hydrogen, or Ry and Ry' together with the nitrogen atom to which they are attached form a cyclic amine such as morpholine, piperidine, piperazine or pyrrolidine; L is NHNH, CH2NH, O or S; Y is NH, NHNH, NHC(=O), S(=O)2NH, NHS(=O)2, CH2, CH2NH, O, S or S(=0)p; Q is aryl or heterocyclyl; Z is O, S, NRa or S(=0)p; m is O, 1 or 2; n is O, 1, 2 or 3; p is independently 1 or 2; q is 0 or 1; Ra is H or C1-C4alkyl; R1 is hydrogen, C1-C6alkyl, C3-C7cycloalkylC0-C3alkyl, arylC0-C3alkyl or heterocyclylC0-C3alkyl, R4'' is H or C1-C6alkyl; or R4' and R4'' together with the carbon atom to which they are attached define a C3-C6cycloalkyl; W is H, C1-C6alkyl, C3-C7ycycloalkyl, aryl or heterocyclyl; or a pharmaceutically acceptable salt, hydrate or N-oxide thereof. The compounds of the invention are inhibitors of aspartyl proteases such as renin and are among other things useful for the treatment of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency.

  该发明提供了以下式（I）的化合物，其中A从部分结构A1、A2和A3中选择；Ry和Ry'都是氢，或者Ry和Ry'与它们连接的氮原子一起形成环状胺，如吗啉、哌啶、哌嗪或吡咯烷；L为NHNH、 NH、O或S；Y为NH、NHNH、NHC(=O)、S(=O)2NH、NHS(=O)2、CH2、 NH、O、S或S(=0)p；Q为芳基或杂环烷基；Z为O、S、NRA或S(=0)p；m为O、1或2；n为O、1、2或3；p独立地为1或2；q为0或1；RA为H或C1-C4烷基；R1为氢、C1-C6烷基、C3-C7环烷基C0-C3烷基、芳基C0-C3烷基或杂环烷基C0-C3烷基，R4''为H或C1-C6烷基；或R4'和R4''与它们连接的碳原子一起定义为C3-C6环烷基；W为H、C1-C6烷基、C3-C7环烷基、芳基或杂环烷基；或其药学上可接受的盐、水合物或N-氧化物。该发明的化合物是天冬氨酸蛋白酶的抑制剂，如肾素，用于治疗与RAS活动相关的疾病，如高血压、心力衰竭和肾功能不全等。
• Cyclic dipeptide enantiomers
  申请人：ICI AUSTRALIA LIMITED

  公开号：EP0304954A2

  公开（公告）日：1989-03-01

  The invention provides novel cyclic dipeptide enantiomers comprising (R)-histidine or a derivative thereof as one of the amino acid residues. These compounds are useful a catalysts for production of (S) -α-­cyanomethyl alcohols from aldehydes.

  本发明提供了一种新颖的环二肽对映体，其中包括(R)-组氨酸或其衍生物作为其中一种氨基酸残基。这些化合物可用作催化剂，用于从醛类产生(S)-α-氰甲基醇。